INVA Earnings Date: Nov 4, 2026 (Estimated) — Innoviva, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is INVA's next earnings date?
Innoviva, Inc. (INVA) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.52 on revenue of $115.3M.
How did INVA do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Innoviva, Inc. posted EPS of -$1.14 versus the $0.44 estimate, a miss of 323.5%. Revenue was $119.6M against a $111.0M estimate. The stock's 1-day post-earnings move was +2.9%.
How much does INVA stock move after earnings?
INVA beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.0% (up or down) in the day after earnings.
About Innoviva, Inc.
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.44 | -1.14 | -323.53% | $119.6M | ❌ Miss | +2.93% | +1.46% | +4.10% |
| 2026-05-06 | Q1 2026 | 0.43 | 2.22 | +416.28% | $98.0M | ✅ Beat | +1.24% | +2.75% | +0.00% |
| 2026-02-25 | Q4 2025 | 0.39 | 1.94 | +397.44% | $114.6M | ✅ Beat | -2.89% | -6.23% | -6.52% |
| 2025-11-05 | Q3 2025 | 0.42 | 1.08 | +157.14% | $107.8M | ✅ Beat | +12.89% | +22.22% | +13.77% |
| 2025-08-06 | Q2 2025 | 0.49 | 0.77 | +57.14% | $100.3M | ✅ Beat | +1.15% | +12.93% | +12.22% |
| 2025-05-07 | Q1 2025 | 0.38 | -0.74 | -294.74% | $88.6M | ❌ Miss | -0.85% | -3.90% | +15.15% |
| 2025-02-26 | Q4 2024 | 0.37 | 0.26 | -29.73% | $91.8M | ❌ Miss | -1.96% | -1.62% | -0.11% |
| 2024-11-06 | Q3 2024 | 0.26 | 0.02 | -92.31% | $89.5M | ❌ Miss | +0.40% | +0.90% | -4.37% |
Showing last 8 quarters.